A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Primary Sarcoma.
Phase of Trial: Phase 0
Latest Information Update: 02 Apr 2018
At a glance
- Drugs ABY 029 (Primary)
- Indications Soft tissue sarcoma
- Focus Diagnostic use
- 28 Mar 2018 Status changed from not yet recruiting to recruiting.
- 31 Jul 2017 Planned initiation date changed to 1 Aug 2017.
- 31 Jul 2017 Status changed from recruiting to not yet recruiting.